Biologics are on the rise!
This article reviews the 7 monoclonal antibodies that are expected to be the best-selling antibody-based drugs in 2024, which focus on inflammation and cancer therapies.
We summarize the landmark studies over the past two decades that established the roles of anti-HER2 antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors in Stage IV metastatic breast cancer.
We summarize the landmark studies over the past two decades that established the roles of anti-EGFR antibodies and TK inhibitors in Stage IV metastatic NSCLC.
Where do we now stand in Alzheimer’s treatment? Here are the clinical trials conducted based on the amyloid cascade hypothesis and future outlook.
What are antibody drug conjugates (ADCs)? How can they be used in cancer therapies? Read on to find out the mechanism of action and recent developments of ADCs.